Abstracts tagged "methotrexate (MTX) and rheumatoid arthritis (RA)"

Abstract Number: 1839 • 2014 ACR/ARHP Annual Meeting
Risk of Recurrent Non-Melanoma Skin Cancer with Methotrexate and Anti-TNF Use in Rheumatoid Arthritis
Frank I Scott¹, Ronac Mamtani¹, Colleen Brensinger¹, Kevin Haynes², Zelma ChiesaFuxench¹, Huifeng Yun³, Jie Zhang⁴, Lang Chen⁵, Fenglong Xie⁶, David Margolis⁷, James D. Lewis² and Jeffrey R. Curtis⁸, ¹University of Pennsylvania, Philadelphia, PA, ²Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ³Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁴Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, ⁵Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁷Dermatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁸The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) and anti-TNF drugs have been hypothesized to increase the risk of a first non-melanoma skin cancer (NMSC). Among patients with prior NMSC,…
Abstract Number: 1488 • 2014 ACR/ARHP Annual Meeting
Clinical Efficacy of Add-on Iguratimod Therapy in Patients with Active Rheumatoid Arthritis Despite of Methotrexate ~a Multicenter Registry Study~
Yasuhide Kanayama¹, Toshihisa Kojima², Atsushi Kaneko³, Yuji Hirano⁴, Nobunori Takahashi², Shinya Hirabara⁴ and Naoki Ishiguro², ¹Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ²Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ⁴Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan
Background/Purpose Iguratimod (IGU) is a small-molecule antirheumatic drug that was approved in Japan in September 2012. IGU suppressed tumor necrosis factor-alpha-induced production of interleukin (IL)-6,…
Abstract Number: 1448 • 2014 ACR/ARHP Annual Meeting
A Questionnaire Assessment of Knowledge about Methotrexate of Patients with Rheumatoid Arthritis
Françoise Fayet¹, Carine Savel¹, Malory Rodere², Bruno Pereira³, Dihya Abdi¹, Marion Couderc Sr.⁴, Sylvain Mathieu⁵, Anne Tournadre⁶, Sandrine Malochet-Guinamand⁶, Martin Soubrier⁷ and Jean Jacques Dubost⁸, ¹Rheumatology, CHU Gabriel-Montpied, Clermont-ferrand, France, ²Rheumatology, CHU Gabriel-Montpied, Clermont-Ferrand, France, ³Clinical research department, Clermont-Ferrand, France, ⁴Chu G.Montpied, Clermont Ferrand, France, ⁵Hopital Gabriel Montpied, Clermont Ferrand, France, ⁶Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, ⁷COMEDRA trial group, Paris, France, ⁸Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France
Background/Purpose Methotrexate is the reference treatment for rheumatoid arthritis (RA). It has potentially serious side effects which can be prevented by an improvement in patient’s…
Abstract Number: 1131 • 2014 ACR/ARHP Annual Meeting
Identification of Genetic Variants Associated with Response to Adalimumab Plus Methotrexate in Patients with Early Rheumatoid Arthritis
Alla Skapenko¹, Hendrik Schulze-Koops¹, Viswanath Devanarayan², Kenneth Idler³, Feng Hong⁴, Josef Smolen⁵, Arthur Kavanaugh⁶, Hartmut Kupper⁷ and Jeffrey F. Waring³, ¹Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ²AbbVie Bioresearch Center, Worcester, MA, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Bioresearch Center, Worchester, MA, ⁵Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁶University of California San Diego, La Jolla, CA, ⁷AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: For patients with rheumatoid arthritis (RA) who fail to attain remission or low disease activity after 6 months of methotrexate (MTX) treatment, TNF inhibitors…
Abstract Number: 1040 • 2014 ACR/ARHP Annual Meeting
Dysregulated Serum Interleukin 16 Concentration Associated with Clinical Disease Activity in Patients with Rheumatoid Arthritis Is Efficiently Corrected By Immunological Intervention
Atsuko Murota¹, Katsuya Suzuki¹, Yoshiaki Kassai², Takahiro Miyazaki³, Rimpei Morita⁴, Akihiko Yoshimura⁴ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Takeda Pharmaceutical Company, Fujisawa, Japan, ³Inflammation Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan, ⁴Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: IL-16 is a chemoattractant factor that evokes massive infiltration of mononuclear cells in the synovial tissue in patients rheumatoid arthritis (RA). IL-16 concentrations are…
Abstract Number: 503 • 2014 ACR/ARHP Annual Meeting
Does a Higher Dose of Folic Acid Reduce Adverse Effects of Methotrexate in Rheumatoid Arthritis? a Randomized Controlled Trial
Varun Dhir¹, Amit Sandhu¹, Jasbinder Kaur², Nidhi Gupta¹, Prabhdeep Kaur¹, Ankita Sood¹, Aman Sharma³ and Shefali Sharma¹, ¹Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Government Medical College and hospital Sector 32, Chandigarh, India, ³Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose There is good evidence that folic acid 5-10mg per week leads to reduction in methotrexate (MTX) toxicity in rheumatoid arthritis (RA). However, this data…
Abstract Number: 2915 • 2014 ACR/ARHP Annual Meeting
Effects of Methotrexate on Anti-TNF Treatment in Rheumatoid Arthritis: An in-Depth Analysis of a Prospective Observational Study with Adalimumab
Marc Schmalzing¹, Frank Behrens^2,3, Eva C. Scharbatke¹, Michaela Koehm^3,4, Bianca Wittig⁵, Gerd Greger⁶, Harald Burkhardt^2,7 and Hans-Peter Tony⁸, ¹Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ²Rheumatology, Goethe-University Frankfurt, Frankfurt, Germany, ³Clinical Research, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ⁴Rheumatology, Goethe-University Frankfurt, Frankfurt/Main, Germany, ⁵Abbvie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁶AbbVie GmbH & Co KG, Wiesbaden, Germany, ⁷Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ⁸Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany
Background/Purpose Methotrexate (MTX) is currently the most frequently used drug in the treatment of rheumatoid arthritis (RA). MTX co-medication can improve the therapeutic benefit of…
Abstract Number: 498 • 2014 ACR/ARHP Annual Meeting
Patient Experience with Initiation of SQ and Oral MTX
Jeffrey R. Curtis¹, David Mackey², Noam Gerber³, Aseem Bharat¹, Lang Chen⁴, Fenglong Xie⁵, Ben Nowell³, Kenneth G. Saag⁶ and Seth Ginsberg⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Creaky Joints/Global Healthy Living Foundation, Upper Nyack, NY, ⁴Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁶Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁷CreakyJoints/Global Healthy Living Foundation, Upper Nyack, NY
Background/Purpose Methotrexate is the anchor drug used for the treatment of rheumatoid arthritis (RA). Despite its prominent position in RA therapeutics, its real-world effectiveness may…
Abstract Number: 2890 • 2014 ACR/ARHP Annual Meeting
Does a Family History of RA Influence the Clinical Presentation and Treatment Response in RA?
Thomas Frisell¹, Saedis Saevarsdottir^2,3 and Johan Askling^1,4, ¹Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Since family history of RA is among the strongest risk factors for developing the disease, individuals suspected to have RA are routinely asked about…
Abstract Number: 470 • 2014 ACR/ARHP Annual Meeting
Safety Profile of Biologic Agents for Rheumatoid Arhtisitis Treatment after the Complication with Methotrexate-Related Lymphoproliferative Disorder
Shuntaro Saito¹, Yuko Kaneko¹, Katsuya Suzuki¹, Michihide Tokuhira² and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Hematology., Saitama Medical Center, Saitama Medical University., Saitama, Japan
Background/Purpose Lymphoproliferative disorder (LPD) is a rare complication in patients with rheumatoid arthritis(RA) treated with methotrexate(MTX). Although not a few patients experience exacerbation of RA…
Abstract Number: 1872 • 2013 ACR/ARHP Annual Meeting
Gene-Body Mass Index Interactions Are Associated With Methotrexate Toxicity in Rheumatoid Arthritis
Stella Aslibekyan¹, Jin Sha¹, David T. Redden², Larry W. Moreland³, James R. O'Dell⁴, Jeffrey R. Curtis⁵, Ted R. Mikuls⁶, S. Louis Bridges Jr.⁷ and Donna K. Arnett¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ³Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Dept of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁷Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Response to methotrexate (MTX) therapy in rheumatoid arthritis (RA) is highly heterogeneous, with both genetic and environmental factors contributing to the efficacy and toxicity…
Abstract Number: 1796 • 2013 ACR/ARHP Annual Meeting
12-Week Results Of a Phase 2b Dose-Ranging Study Of Baricitinib, An Oral JAK1/ JAK2 Inhibitor In Japanese Patients With Rheumatoid Arthritis On Background Methotrexate Therapy
Yoshiya Tanaka¹, Kahaku Emoto², Mika Tsujimoto², Douglas E. Schlichting³ and William Macias³, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Eli Lilly Japan K.K., Kobe, Japan, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (formerly LY3009104/INCB028050), a novel, oral inhibitor of JAK1 and JAK2 in the JAK-STAT signaling pathway, has been evaluated in a 12-week blinded phase…
Abstract Number: 1467 • 2013 ACR/ARHP Annual Meeting
Adalimumab In Combination With High and Low Dose-Methotrexate In Rheumatoid Arthritis Patients With Inadequate Response To Methotrexate: Pharmacokinetic Results From The Musica Study
Ghada Ahmed¹, Sandra L Goss¹, Cheri E Klein¹, Neelufar Mozaffarian², Gurjit S. Kaeley³ and Walid Awni¹, ¹AbbVie Inc., North Chicago, IL, ²Eli Lilly, San Diego, CA, ³College of Medicine, University of Florida, Jacksonville, FL
Background/Purpose: Rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX) may be initiated on combination therapy with anti-TNF agents such as adalimumab. However, it…
Abstract Number: 1445 • 2013 ACR/ARHP Annual Meeting
GEMS Audit: An Evaluation Of Routine Use Of Subcutaneous Methotrexate In Rheumatoid Arthritis
Esme Roads¹, Scot Buchan² and Charles Li³, ¹Royal Surrey County Hospital, Guildford, United Kingdom, ²Strategen Ltd, Basingstoke, United Kingdom, ³Rheumatology, Royal Surrey County Hospital, Guildford, United Kingdom
Background/Purpose: Methotrexate (MTX) forms the backbone of treatment for the majority of patients with rheumatoid arthritis (RA), and is advocated in most guidelines.[i],[ii],[iii] Existing studies imply…
Abstract Number: 1420 • 2013 ACR/ARHP Annual Meeting
Induction Therapy With Adalimumab On Top Of An Aggressive Treat-To-Target Strategy With Methotrexate and Intraarticular Corticosteroid Reduces Radiographic Erosive Progression In Early Rheumatoid Arthritis, Even After Withdrawal Of Adalimumab. Results Of a 2-Year Trial (OPERA)
Kim Hørslev-Petersen¹, Lykke Midtbøll Ørnbjerg², Merete Lund Hetland³, Peter Junker⁴, Jan Pødenphant⁵, Torkell Ellingsen⁶, Palle Ahlqvist⁷, Hanne M. Lindegaard⁸, Asta Linauskas⁹, Annette Schlemmer¹⁰, Mette Y. Dam¹¹, Ib Hansen¹², Tine Lottenburger⁷, Anette Jørgensen¹³, Sophine B. Krintel¹⁴, Johnny Raun¹⁵, Christian G. Ammitzbøll¹¹, Julia Johansen¹⁴, Mikkel Østergaard¹⁶ and Kristian Stengaard-Pedersen¹¹, ¹Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, ²Copenhagen Center for Arthritis Reasearch, Center for Rheumatology and Spine diseases, Glostrup Hospital, Copenhagen, Denmark, ³DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ⁴University of Southern Denmark, Odense, Denmark, ⁵Copenhagen University at Gentofte, Hellerup, Denmark, ⁶Silkeborg Regional Hospital, Silkeborg, Denmark, ⁷University of Southern Denmark, Vejle, Denmark, ⁸Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁹Vendsyssel Hospital, Hjørring, Denmark, ¹⁰Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹¹Arhus University Hospital, Aarhus, Denmark, ¹²Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹³Rheumatology, Arhus University Hospital, Aarhus, Denmark, ¹⁴Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, ¹⁵University of Southern Denmark, Graasten, Denmark, ¹⁶Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: In a randomized double-blind, placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis¹ (RA) we aimed to investigate if additional adalimumab (ADA) for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.